(19)
(11) EP 3 423 094 A1

(12)

(43) Date of publication:
09.01.2019 Bulletin 2019/02

(21) Application number: 16891935.5

(22) Date of filing: 29.02.2016
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
A61P 3/08(2006.01)
A61P 3/04(2006.01)
A61P 3/10(2006.01)
(86) International application number:
PCT/CN2016/074809
(87) International publication number:
WO 2017/147742 (08.09.2017 Gazette 2017/36)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

(71) Applicant: Eli Lilly and Company
Indianapolis, IN 46285 (US)

(72) Inventor:
  • WU, Xinle
    Indianapolis, Indiana 46206-6288 (US)

(74) Representative: Bassinder, Emma Marie et al
Eli Lilly and Company Limited European Patent Operations Erl Wood Manor Sunninghill Road
Windlesham, Surrey GU20 6PH
Windlesham, Surrey GU20 6PH (GB)

   


(54) GFRAL RECEPTOR THERAPIES